Cargando…

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms

Torsemide is a diuretic drug used for several cardiovascular and chronic diseases. With regard to the clinical application of torsemide, studies on individualized pharmacotherapy and modeling that take variability in pharmacokinetics (PKs) within a population into account have been rarely reported....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Seung-Hyun, Jang, Ji-Hun, Cho, Hea-Young, Lee, Yong-Bok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028991/ https://www.ncbi.nlm.nih.gov/pubmed/35456605 http://dx.doi.org/10.3390/pharmaceutics14040771

Ejemplares similares

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling
por: Jeong, Seung-Hyun, et al.
Publicado: (2022)

Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans
por: Jang, Ji-Hun, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses
por: Agne, Gustavo F., et al.
Publicado: (2018)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

A case of bullous pemphigoid induced by torsemide
por: Wurtz, Paul, et al.
Publicado: (2022)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
por: Wang, Zhiqi, et al.
Publicado: (2019)

CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide
por: Yang, Fayou, et al.
Publicado: (2018)

Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations
por: Li, R, et al.
Publicado: (2014)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers
por: Park, Sunny, et al.
Publicado: (2017)

Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C Polymorphisms and Overall Survival of Breast Cancer Patients after Tamoxifen Therapy
por: Zhang, Xuefeng, et al.
Publicado: (2015)

Proteomic differences among patients with heart failure taking furosemide or torsemide
por: Cooper, Lauren B., et al.
Publicado: (2022)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
por: Nebot, Noelia, et al.
Publicado: (2021)

The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients
por: Chopra, V. K, et al.
Publicado: (2023)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
por: F. Martins, Margarida L., et al.
Publicado: (2022)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions
por: Alam, Khondoker, et al.
Publicado: (2018)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation
por: Woillard, Jean-Baptiste, et al.
Publicado: (2017)

Selectivity and Potency of Microcystin Congeners against OATP1B1 and OATP1B3 Expressing Cancer Cells
por: Niedermeyer, Timo H. J., et al.
Publicado: (2014)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action
por: Shah, Salim, et al.
Publicado: (2017)

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates
por: Haberer, Lynda J., et al.
Publicado: (2013)

Localization of organic anion transporting polypeptide (Oatp) 1a4 and Oatp1c1 at the rat blood-retinal barrier
por: Akanuma, Shin-ichi, et al.
Publicado: (2013)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
por: Suga, Takahiro, et al.
Publicado: (2017)

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
por: Schnegelberger, Regina D., et al.
Publicado: (2022)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin
por: Cestari, Roberta Natália, et al.
Publicado: (2020)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells
por: Brännström, Marie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ak2csvecm6qc4vcn3mbiev3edp